A 32-year-old man presented with bloody diarrhea of new onset. For three days he had had 10 to l5 bowel movements per day containing bright red blood. He also had had one black, tarry stool, but no fever, chills, nausea, vomiting, or constipation. Upper gastrointestinal endoscopy revealed acute gastritis, and colonoscopy was interpreted as unremarkable; he was then transferred to our institution for further workup.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Ischemic colitis presenting as a colonic mass: a case report and diagnostic challenges.
Front Med (Lausanne)
January 2025
Institute of Gastroenterology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Ischemic colitis (IC) is a multifaceted condition that often manifests with nonspecific symptoms such as abdominal pain and bloody diarrhea, particularly in older adults with vascular risk factors. Diagnosis is supported by elevated levels of white blood cells, lactate, and C-reactive protein (CRP). Computed tomography (CT) imaging typically reveals wall thickening and fat stranding in watershed areas.
View Article and Find Full Text PDFA Parasite That Should not be Neglected in Patients with Ulcerative Colitis: .
Turkiye Parazitol Derg
January 2025
Erzincan Binali Yıldırım University Faculty of Medicine, Department of Medical Microbiology, Erzincan, Türkiye.
Objective: To determine the prevalence of amoebiasis, which has been neglected in recent years according to the World Health Organization, in ulcerative colitis patients and investigate the relationship between amoebiasis and ulcerative colitis.
Methods: The study included 150 individuals, including 100 ulcerative colitis patients and 50 healthy individuals without gastrointestinal complaints. The samples collected were first analyzed macroscopically and then using native-Lugol, trichrome staining, and enzyme-linked immunosorbent assay (ELISA).
Clinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease.
Eur J Med Res
January 2025
Department of Clinical Pharmacy, Xiangtan Central Hospital (The affiliated hospital of Hunan university), 120 Heping Road, Yuhu District, Xiangtan, 411100, Hunan, China.
Background: Inflammatory bowel disease (IBD) is a rare adverse effect linked to secukinumab, with limited clinical data available. This study aimed to analyze the clinical features of secukinumab-induced IBD and to offer recommendations for the careful administration of secukinumab.
Methods: We conducted a retrospective analysis by gathering case reports and case series of secukinumab-induced IBD through a database search, with data collected until September 30, 2024.
Treatment of immune checkpoint inhibitor-related colitis: a narrative review.
Transl Cancer Res
December 2024
Division of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Background And Objective: Cancer is one of the most difficult diseases facing modern medicine, and increasing amounts of research and clinical treatments are being applied to the treatment of cancer. Immunotherapy, particularly immune checkpoint inhibitor (ICI) therapy, has revolutionized the treatment and overall survival of patients with several different types of cancer. Approximately one-third of patients treated with ICIs may experience immune-related adverse events (irAEs).
View Article and Find Full Text PDFParadoxical Inflammatory Bowel Disease Induced by Golimumab in a Patient With Ankylosing Spondylitis: A Case Report and Systematic Review.
Cureus
January 2025
Faculty of Medicine, University of Hama, Hama, SYR.
Paradoxical reactions (PRs) to biologic medications, such as psoriasis, arthritis, and inflammatory bowel disease (IBD), have been increasingly recognized. The aim of reporting this case is to establish an association between golimumab and exacerbation or new (de novo) IBD in patients with axial spondyloarthritis (SpA). Our case involves a young patient with juvenile-onset ankylosing spondylitis (AS) who developed de novo IBD following golimumab therapy for active spinal disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!